The Impact of Abuse Deterrent Technologies on Prescription Opioid Trends
Published Online: October 11, 2013
Howard Oremland, RPh, MBA; Lauren G. Gallagher, MPH; John Schlie, PharmD; Dick Creager, MD, MPA; Anthony Palmieri, PharmD, MBA; Olga S. Matlin, PhD; and Steven M. Kymes, PhD
The past 2 decades have been marked by an increased awareness of the need for improved management of chronic pain and the aggressive marketing of new opioid formulations. This has been associated with an increased prevalence in prescribing of opioids, alongside an increase in the abuse of prescription drugs. In response, the Centers for Disease Control and Prevention (CDC) has described prescription drug abuse as the fastest-growing drug abuse problem in the United States.1
Oxycontin (Purdue Pharmaceuticals, LP) is a controlled-release oxycodone first sold in 1995 and is today among the most widely prescribed opioid medications. The controlled-release formulation is expected to deter abuse, as the active ingredient is released over a specified time period, reducing the patient’s ability to seek a “high” by taking more medication than prescribed. However, prescription drug abusers can achieve an enhanced high by chewing, crushing and snorting, or liquefying the pills. To inhibit this behavior Purdue developed an abuse deterrent technology version of Oxycontin that was approved for sale by the US Food and Drug Administration (FDA) in April 2010; and in August 2010, the company began limiting sales exclusively to the abuse deterrent technology formulation.2 A 2012 survey of 2566 opioiddependent patients conducted in part to assess the impact of the abuse deterrent technology on opioid abuse behavior reported that following release of the abuse deterrent formulation, there was indeed a decline in Oxycontin as a primary drug of abuse. However, this was accompanied by increased use of hydrocodone and other oxycodone agents, as well as increased use of high-potency agents such as fentanyl, hydromorphone and heroin.3
We analyzed de-identified prescription drug claims to examine the impact of abuse deterrent formulations on the utilization of opioid medications. We specifically considered the impact of the introduction of an abuse deterrent formulation of controlled-release Oxycontin on medication utilization in a cohort of prescription drug benefit plan members who were long-term users of Oxycontin at the time of the release of the abuse deterrent formulation in August 2010.
This analysis was conducted using de-identified CVS Caremark pharmacy benefit claims data. Prescription drug benefit members who had at least 1 pharmacy claim in calendar years between 2009 and 2012 for medications commonly used to treat pain were selected for analysis (Table 1). Members with claims for antineoplastic medications were excluded to limit the analysis to members with pain not related to cancer. Our analyses were limited to opioid medications categorized as follows: Oxycontin, other oxycodones (including generic versions of Oxycontin), morphine sulfate, hydrocodone-acetaminophen combinations, and other opioid-based pain medications(eg, fentanyl, oxymorphone, tramadol).
We examined medication utilization rates among chronic and acute opioid users, measured as the number of prescriptions filled per 1000 eligible prescription drug benefit eligible members per year from 2009 to 2012. In addition, we examined utilization trends among chronic opioid users to identify changes in medication selection following introduction of abuse deterrent technology formulations in August 2010. For this second analysis we compared 2 cohorts: 1) patients who received at least a 90-day supply of Oxycontin during the 6 months before the introduction in 2010 of Oxycontin with abuse deterrent technology; and 2) a comparison group of patients who received at least a 90-day supply of Oxycontin during the 6 months prior to August 2009. Both cohorts were limited to members for whom Oxycontin was the only pain medication used during the 6-month look-back period. The outcomes of prescription drug use in the 12-month follow-up period (August to July) were: 1) patient remained on Oxycontin only; 2) patient discontinued all prescription opioid medications; 3) patient changed to a prescription opioid medication other than Oxycontin; and 4) patient added another prescription opioid to the Oxycontin regimen. We compared thpattern of utilization in the post period between these groups using the χ2 statistic. All analyses were conducted using SAS 9.1 (SAS Institute, Cary, North Carolina).
During each year from 2009 to 2012, approximately 4 million unique members from the analytic data set fi lled at least 1 prescription for an opioid pain medication and met our inclusion and exclusion criteria. The average age of members with a prescription for pain medication was 44.7 years (standard deviation ± 18.3) and 56% of opioid users were female.
Of the total prescriptions filled for opioid medication, over 99% were fi lled at retail pharmacies, 52% were for 10 days or less, and an additional 13% were for 11 to 20 days. Hydrocodone-acetaminophen combinations were the largest category of opioids, accounting for over half of all opioids prescribed. The overall rate of opioid use decreased by 8.3% between 2009 and 2012 (Table 2), with the even larger decreases observed in utilization of Oxycontin, morphine sulfate, and hydrocodoneacetaminophen combinations (19%, 10.5%, and 12.9% decreases, respectively).
The results of our analyses comparing a cohort of members who were Oxycontin users at the time abuse deterrent technology was introduced in August 2010 to a similar cohort of users in August 2009 are presented in Table 3. In both cohorts, approximately 10% discontinued use of all opioid medications during the year of follow-up. In the cohort that were chronic Oxycontin users in August 2009 (the year prior to the introduction of the abuse deterrent formulation), 2.2% of members switched to another opioid medication during the subsequent 12 months. Among members who were chronic Oxycontin users in August 2010 (when the new technology was introduced), 2.6% switched to a new opioid after the introduction of the abuse deterrent formulation. The differences between these cohorts were not statistically significant (P = 0.68).
Discussion of Findings and Pipeline Therapies
The purpose of abuse deterrent technologies is to reduce the social and medical burden associated with prescription drug abuse. In our analyses, we found that in the years following introduction of the abuse deterrent formulation, there has been a decline in utilization of Oxycontin among acute and chronic users of the medication. However, the evidence that this might be due to the abuse deterrent formulation is far from clear. The decline in use of opioid medications across other categories, noneof which included abuse deterrent formulations, may indicate that there are other market reasons for the shift away from Oxycontin. In addition, we examined changes in prescription preference for chronic Oxycontin users who purchased their medication through their pharmacy benefit plan. There we found no evidence of a negative impact on Oxycontin use among these chronic users following introduction of the abuse deterrent technology.
Previous studies of the impact of abuse deterrent formulation on opioid abuse reported mixed results.2,3 It has been argued that prescription opiate abuse is a complex health problem that requires a comprehensive, multifaceted solution, and thus resists a single solution.4 Indeed, many have noted that targeting abuse deterrent technology to a single medication alone is an ineffective strategy, as an effective restriction would require that all opiate formulations employ the technology.2,5-7 However, most recognize that in addition to the regulatory hurdles such a policy change would encounter, there would be substantially increased cost to individuals and global health budgets resulting from such a restriction.5,7,8
We found that across all categories of opioids, the rate of prescriptions dispensed fell by 8.3% for prescription drug benefit members between 2009 and 2012. It has been reported that between 2001 and 2012 the annual number of prescriptions written for opioids in the United States increased by 33%9; however, most of this increase occurred prior to 2005.10 Since 2009 sales of hydrocodone-acetaminophen combinations and oxycodone hydrochloide have been flat nationally11 while worldwide sales of branded Oxycontin have declined.12 It should be noted that our data only include sales of opioids to prescription drug benefit members using their pharmacy benefit. There remains a very large market of cash sales that cannot be captured in our data, and therefore the trends of purchasing and utilization of opioid medications obtained via cash transactions were not examined in this analysis.
In April 2013, the FDA approved updated labeling for the reformulated, abuse deterrent version of controlled release oxycodone hydrochloride indicating continued support of regulators for abuse deterrent technologies in both generic and branded medications.13 In Table 4,14-19 we detail the pipeline for abuse deterrent technologies for other opioid based analgesics. The pipeline includes a wide array of technologies with functionality that would limit the ability of abusers to tamper with the drug. The medications in development include traditional opioid treatments for moderate to severe pain that incorporate agonist/antagonist, aversion, and physical or chemical barrier technologies. Remoxy, an oxycodone controlled release product, appears to be a future candidate for FDA approval; however, Pfizer has not yet invested in further development.
Abuse deterrent formulations continue to evolve and find application across a range of therapeutic classes and interest from public policy makers. Prescription drug abuse shows no signs of abating as a social problem; therefore, there is a growing need for formulary policy makers to be aware of the clinical and economic impact of abuse deterrent technologies.
Author Affiliations: From the Division of Enterprise Analytics (LG, OSM, SMK), CVS Caremark, Northbrook, IL; Clinical Sales and Account Services (HO, JS, AP), CVS Caremark, Scottsdale AZ; and Medical Affairs (DC), CVS Caremark, Northbrook IL
Funding Source: None reported.
Author Disclosures and Disclaimers: The authors report no relationship or fi nancial interest with any entity that would pose a confl ict of interest with the subject matter of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of CVS Caremark. This document contains confi dential and proprietary information of CVS Caremark and cannot be reproduced, distributed, or printed without written permission from CVS Caremark. This document contains references to brand name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this communication is provided in summary form. It is not intended for use as the sole basis of clinical treatment, as a substitute for reading the original research, nor as a substitute for the knowledge, skill, and judgment of a medical provider. Plan member privacy is important to CVS Caremark. Our employees are trained regarding the appropriate way to handle members’ private health information. ©2013 Caremark. All rights reserved.
Address correspondence to: Steven M. Kymes, PhD, CVS Caremark, 2211 Sanders Rd, NBT 326, Northbrook, IL 60062. E-mail: Steven .Kymes@caremark.com.
1. Office of National Drug Control Policy. Epidemic: responding to America’s prescription drug crisis. http://www.whitehouse.gov/sites/default/fi les/ondcp/issuescontent/prescription-drugs/rx_abuse_plan_0.pdf. Accessed June 30, 2013.
2. Schaeffer T. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol. 2012;8(4):400-407.
3. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of Oxy-Contin. N Engl J Med. 2012;367(2):187-189.
4. Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs. 2012;72(13):1713-1723.
5. Webster L, St Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E. Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. J Opioid Manag. 2011;7(3):235-245.
6. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10(1):11-18.
7. Romach MK, Schoedel KA, Sellers EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend. 2013;130(1-3):13-23.
8. Lourenco LM, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use? Expert Opin Drug Deliv. 2013;10(2):229-240.
9. Meier B, Marsh B. The soaring cost of the opioid economy. New York Times. June 22, 2013;The Opinion Pages.
10. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12): 1166-1175.
11. Aitken M, Kleinrock M. Declining Medicine Use and Costs: For Better or Worse? A Review of the Use of Medicines in the United States in 2012. Parsippany, NJ: IMS Institute for Healthcare Informatics; May 2013.
12. Glover S. OxyContin maker closely guards its list of suspect doctors. Los Angeles Times. August 11, 2013.
13. Wilson MR. FDA acts quickly on blocking Oxycontin generics. The Hill. April 16, 2013.
14. Acura Pharma jumps on Nexafed pharmacy deal, http://news.yahoo.com/acura-pharma-jumps-nexafed-pharmacy-164242905.html#/%7Burl%7D. Published March 5, 2013. Accessed June 27, 2013.
15. Pain Therapeutics, Inc. Pipeline. http://www.paintrials.com/remoxy.html#.Published 2013. Accessed June 27, 2013.
16. Durect. Science and technologies. http://www.durect.com/wt/durect/page_name/oradur. Published 2013. Accessed June 27, 2013.
17. Pfizer announces top-line results from a phase 3 long-term safety study Of ALO-02: an investigational agent comprised of oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules, in subjects with moderate-to-severe chronic non-cancer pain. http://press.pfi zer.com/press-release/pfi zerannounces-top-line-results-phase-3-long-term-safety-study-alo-02. Published 2012. Accessed June 30, 2013.
18. Relmada Therapeutics. Development pipeline. http://www.relmada.com/development-pipeline/pain-candidate-TQ-1020-levorphanol-extended-release.htm. Published 2013. Accessed June 30, 2013.
19. Collegium Pharmaceutical. DETERx formulation design. http://www.collegiumpharma.com/deterxatrade-formulation-design. Published 2013. Accessed June 30, 2013.